보고서 요약(국문)

개요
글로벌 치료용 혈장 교환 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
치료용 혈장 교환(TPE)은 환자의 혈액을 성분채집기를 통과시켜 여과된 혈장을 제거하고 폐기하는 시술이며, 적혈구와 혈장 또는 알부민과 같은 대체 용액을 환자에게 재주입합니다. 당사는 다양한 신경계 및 비신경계 질환 치료에 있어 TPE를 적용한 경험을 제시합니다. 혈장분리술이라고도 하는 치료용 혈장 교환(TPE)은 특정 질환 치료를 위해 환자의 혈장을 제거하고 대체하는 시술입니다.
시장 동향: 동인 및 제약 요인
자가면역 질환 유병률 증가
치료용 혈장 교환은 다양한 자가면역 질환 치료에 자주 사용됩니다. 류마티스 관절염, 루푸스, 길랭-바레 증후군과 같은 자가면역 질환의 유병률 증가는 치료적 혈장 교환에 대한 수요 증가에 기여하고 있습니다.
예를 들어, 존스 홉킨스 대학교의 최신 자료에 따르면, 학자들은 발표된 논문과 스칸디나비아 국가와 같이 역학 자원이 풍부한 소규모 국가의 1차 데이터를 기반으로 자가면역 질환이 미국 인구의 약 3%, 즉 약 1천만 명에게 영향을 미치는 것으로 추정합니다. 이 추정치는 현재 미국 인구 3억 2,900만 명을 기준으로 합니다.
또한, 치료적 혈장 교환 시장은 의료 기술의 발전, 의료비 지출 증가, 규제 지원 및 승인 등 다양한 요인에 의해 성장하고 있으며, 이러한 요인들은 예측 기간 동안 시장 성장을 촉진할 것입니다.
시장 동향: 제약 요인
혈장 분리 장치의 비용은 의료 서비스 제공자와 궁극적으로 환자의 혈장 교환 도입 여부를 결정하는 중요한 요소입니다. 혈액 은행에서는 혈액 성분 수집에, 병원에서는 치료적 혈장 교환 시술에 이러한 장치를 사용합니다. 혈장분리술 장비와 소모품의 높은 가격 또한 혈장분리술 시술의 전체 비용을 증가시킵니다. 예를 들어, 미국에서 혈장분리술 시술 비용은 회당 약 2,500달러입니다. 환자들은 높은 비용 때문에 이러한 시술을 선택하지 않을 수도 있습니다.
세분화 분석
전 세계 치료용 혈장 교환 시장은 제품 유형, 적응증, 최종 사용자 및 지역별로 세분화됩니다.
제품 유형 부문에서 혈장분리술은 치료용 혈장 교환 시장 점유율의 약 43.7%를 차지했습니다.
제품 유형 부문에서 혈장분리술은 약 43.7%를 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 혈장분리술은 환자 또는 기증자로부터 전혈을 채취하는 과정입니다. 원심분리기와 유사한 장비를 사용하여 전혈의 구성 성분을 분리합니다. 분리된 성분 중 일부는 채취하고 나머지 성분은 환자 또는 기증자에게 수혈합니다.

예를 들어, 혈액 성분 채집, 치료적 성분채집술 및 세포 기술 분야의 제품, 소프트웨어 및 서비스 포트폴리오를 전문으로 하는 의료 기술 회사인 테루모 혈액 및 세포 기술(Terumo Blood and Cell Technologies)은 2022년 6월, 영국 국민보건서비스(NHS England)가 NHS 의료기술 기금 지원 의무(MTFM)를 통해 자사의 스펙트라 옵티아 성분채집 시스템(Spectra Optia Apheresis System)에서 수행되는 자동 적혈구 교환(RBCX) 시술을 겸상 적혈구 질환 치료에 채택했다고 발표했습니다.
지역 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 전 세계적으로 다양한 자가면역 질환의 유병률 증가, FDA 승인, 관상동맥 질환(CAD), 고콜레스테롤혈증, 뇌졸중 및 동맥경화증과 같은 심혈관 질환에 대한 지질단백질 성분채집술 치료의 채택 증가, 그리고 최근 몇 년간 심장 관련 사망률 증가 등의 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.

예를 들어, 2023년 10월 글로벌 바이오제약 회사인 UCB(유로넥스트 브뤼셀: UCB)는 질브리스큐(ZILBRYSQ, 질루코플란)가 항아세틸콜린 수용체(AChR) 항체 양성 성인 환자의 전신성 중증근무력증(gMG) 치료제로 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. 질브리스큐는 정맥 면역글로불린 및 혈장 교환과 병용 투여가 가능하며, 추가 투여는 필요하지 않습니다.
COVID-19 영향 분석
치료적 혈장 교환(TPE)은 다양한 원인의 패혈증, 인플루엔자 감염, 이차성 혈구탐식성 림프조직구증(HLH) 등 COVID-19 감염과 유사한 질환에 적용되었습니다.
치료적 혈장 교환은 수십 년 동안 중증 패혈증의 대체 치료법으로 사용되어 왔지만, 결과는 일관되지 않았습니다. 중증 패혈증에서 혈장 교환을 권장할 만한 명확한 증거는 없지만, 몇몇 연구에서는 이 질환에서 혈장 교환의 역할을 뒷받침하며, 치료를 받은 패혈증 환자에서 혈역학적 안정성과 응고 불균형이 개선되었다고 제시합니다.
시장 세분화
제품 유형별
• 혈장분리기
• 필터
• 기타
적응증별
• 신경계 질환
• 심혈관계 질환
• 혈액 질환
• 신장 질환
• 기타
최종 사용자별
• 병원
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Asahi Kasei Corporation, Baxter International Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Haemonetics Corporation 등이 있습니다. Kawasumi Laboratories, Adcem Healthcare, Kochin Inlab Equipments India Pvt Ltd, Miltenyi Biotec 등이 주요 업체입니다.

주요 개발 사항
 2022년 1월, Beckman Coulter는 두바이 세계 무역 센터에서 개최된 MEDLAB Middle East 2022에서 DxA 5000 Fit 워크플로우 자동화 시스템을 선보였습니다.

보고서 구매 이유

• 제품 유형, 방식, 적용 분야, 최종 사용자 및 지역별 글로벌 치료용 혈장 교환 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 치료용 혈장 교환 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 치료용 혈장 교환 시장 보고서는 약 69개의 표, 70개의 그림, 그리고 183페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Therapeutic Plasma Exchange Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Therapeutic Plasma Exchange (TPE) is a procedure in which the patient’s blood is passed through an apheresis machine, where the filtered plasma is removed and discarded with reinfusion of red blood cells along with replacement fluid such as plasma or albumin into the patient. We present our experience with TPE in the treatment of various neurologic and non-neurologic diseases. Therapeutic plasma exchange (TPE), also known as plasmapheresis, removes and replaces a patient's blood plasma to treat certain diseases.
Market Dynamics: Drivers and Restraints
Rise in the prevalence of autoimmune diseases
Therapeutic plasma exchange is often used in the treatment of various autoimmune disorders. The rising prevalence of autoimmune diseases such as rheumatoid arthritis, lupus, and Guillain-Barré syndrome contributes to the demand for therapeutic plasma exchange.
For instance, according to Johns Hopkins University's updated factsheet, Scholars estimate that autoimmune diseases affect about 3% of the US population, or approximately 10 million people, based on published papers and primary data from smaller countries with excellent epidemiological resources, such as Scandinavian countries. This estimate is based on the current US population of 329 million.
Furthermore, the therapeutic plasma exchange market is also driven by various other factors like advancements in medical technology, rising healthcare expenditure, regulatory support and approvals and others that help the market to grow during the forecast period.
Market Dynamics: Restraint
The cost of apheresis devices is a critical factor in determining the adoption of plasma exchange by healthcare providers and, ultimately, by patients. Apheresis devices are used by blood banks for blood component collection, while hospitals use these devices for therapeutic plasma exchange procedures. The high cost of apheresis devices and disposables also increases the overall cost of apheresis procedures. For instance, in the US, the cost of an apheresis procedure is —USD 2,500 per treatment. Patients might not opt for these procedures owing to their high cost.
Segment Analysis
The global therapeutic plasma exchange market is segmented based on product type, indication, end-user and region.
The apheresis from the product type segment accounted for approximately 43.7% of the therapeutic plasma exchange market share
The apheresis from the product type segment accounted for approximately 43.7% and is expected to dominate during the forecast period. The process of apheresis involves the removal of whole blood from a patient or donor. Within an instrument that is essentially designed as a centrifuge, the components of whole blood are separated. One of the separated portions is then withdrawn and the remaining components are transfused into the patient or donor.
For instance, in June 2022, Terumo Blood and Cell Technologies, a medical technology company specializing in a portfolio of products, software and services for blood component collection, therapeutic apheresis and cellular technologies, stated the UK’s NHS England has selected the automated red blood cell exchange (RBCX) procedure performed on the company’s Spectra Optia Apheresis System through the NHS MedTech Funding Mandate (MTFM) to treat sickle cell disease.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors rise in the global prevalence of various autoimmune disorders, FDA approvals, rise in the adoption of lipoprotein apheresis treatment for cardiovascular indications like CAD, hypercholesterolemia strokes and atherosclerosis with an increased rate of cardiac deaths in recent years.
For instance, in October 2023, UCB (Euronext Brussels: UCB), a global biopharmaceutical company, stated that ZILBRYSQ (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. ZILBRYSQ can be used concomitantly with intravenous immunoglobulin and plasma exchange, without the need for supplemental dosing.
COVID-19 Impact Analysis
In the course of using TPE, the procedure was applied in diseases with similarities to COVID-19 infection, such as sepsis due to various causes, influenza infection and Secondary Hemophagocytic Lymph histiocytosis (HLH).
Therapeutic plasma exchange has been used as an alternative treatment in severe sepsis for several decades, with conflicting results. Although there is no clear evidence to recommend plasma exchange in severe sepsis, there are a few studies supporting the role of TPE in this entity, suggesting improvement in hemodynamic stability and coagulation disbalance in septic patients receiving the treatment.
Market Segmentation
By Product Type
• Apheresis Machine
• Filters
• Others
By Indication
• Neurological Disorders
• Cardiovascular Disorders
• Hematology Disorders
• Renal Disorders
• Others
By End-User
• Hospitals
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Asahi Kasei Corporation., Baxter International Inc., Terumo Corporation., B. Braun Melsungen AG., Fresenius Kabi AG., Haemonetics Corporation, Kawasumi Laboratories, Adcem Healthcare, Kochin Inlab Equipments India Pvt Ltd, Miltenyi Biotec and among others.
Key Developments
 In January 2022, Beckman Coulter displayed its launched DxA 5000 Fit workflow-automation system at the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre.
Why Purchase the Report?
• To visualize the global therapeutic plasma exchange market segmentation based on product type, modality, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of therapeutic plasma exchange market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global therapeutic plasma exchange market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of autoimmune diseases
4.1.1.2. Advancements in the technology
4.1.2. Restraints
4.1.2.1. High cost associated with the systems
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Apheresis *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Filters
7.4. Others
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Neurological Disorders *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Disorders
8.4. Hematology Disorders
8.5. Renal Disorders
8.6. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Asahi Kasei Corporation*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Baxter International Inc.
12.3. Terumo Corporation.
12.4. B. Braun Melsungen AG.
12.5. Fresenius Kabi AG.
12.6. Haemonetics Corporation
12.7. Kawasumi Laboratories
12.8. Adcem Healthcare
12.9. Kochin Inlab Equipments India Pvt Ltd
12.10. Miltenyi Biotec
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Asahi Kasei Corporation, 4.	Key Developments, Baxter International Inc., Terumo Corporation., B. Braun Melsungen AG., Fresenius Kabi AG., Haemonetics Corporation, Kawasumi Laboratories, Adcem Healthcare, Kochin Inlab Equipments India Pvt Ltd, Miltenyi Biotec

표 목록 (Tables)

List of Tables

Table 1 Global Therapeutic Plasma Exchange Market Value, By Product Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Therapeutic Plasma Exchange Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Therapeutic Plasma Exchange Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Therapeutic Plasma Exchange Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Therapeutic Plasma Exchange Market Value, By Product Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Therapeutic Plasma Exchange Market Value, By Product Type, 2021-2030 (US$ Million)

Table 7 Global Therapeutic Plasma Exchange Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Therapeutic Plasma Exchange Market Value, By Indication, 2021-2030 (US$ Million)

Table 9 Global Therapeutic Plasma Exchange Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Therapeutic Plasma Exchange Market Value, By End-User, 2021-2030 (US$ Million)

Table 11 Global Therapeutic Plasma Exchange Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Therapeutic Plasma Exchange Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Therapeutic Plasma Exchange Market Value, By Product Type, 2021-2030 (US$ Million)

Table 14 North America Therapeutic Plasma Exchange Market Value, By Indication, 2021-2030 (US$ Million)

Table 15 North America Therapeutic Plasma Exchange Market Value, By End-User, 2021-2030 (US$ Million)

Table 16 North America Therapeutic Plasma Exchange Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Therapeutic Plasma Exchange Market Value, By Product Type, 2021-2030 (US$ Million)

Table 18 South America Therapeutic Plasma Exchange Market Value, By Indication, 2021-2030 (US$ Million)

Table 19 South America Therapeutic Plasma Exchange Market Value, By End-User, 2021-2030 (US$ Million)

Table 20 South America Therapeutic Plasma Exchange Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Therapeutic Plasma Exchange Market Value, By Product Type, 2021-2030 (US$ Million)

Table 22 Europe Therapeutic Plasma Exchange Market Value, By Indication, 2021-2030 (US$ Million)

Table 23 Europe Therapeutic Plasma Exchange Market Value, By End-User, 2021-2030 (US$ Million)

Table 24 Europe Therapeutic Plasma Exchange Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Therapeutic Plasma Exchange Market Value, By Product Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Therapeutic Plasma Exchange Market Value, By Indication, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Therapeutic Plasma Exchange Market Value, By End-User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Therapeutic Plasma Exchange Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Therapeutic Plasma Exchange Market Value, By Product Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Therapeutic Plasma Exchange Market Value, By Indication, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Therapeutic Plasma Exchange Market Value, By End-User, 2021-2030 (US$ Million)

Table 32 Asahi Kasei Corporation: Overview

Table 33 Asahi Kasei Corporation: Product Portfolio

Table 34 Asahi Kasei Corporation: Key Developments

Table 35 Baxter International Inc: Overview

Table 36 Baxter International Inc: Product Portfolio

Table 37 Baxter International Inc: Key Developments

Table 38 Terumo Corporation: Overview

Table 39 Terumo Corporation: Product Portfolio

Table 40 Terumo Corporation: Key Developments

Table 41 B. Braun Melsungen AG: Overview

Table 42 B. Braun Melsungen AG: Product Portfolio

Table 43 B. Braun Melsungen AG: Key Developments

Table 44 Fresenius Kabi AG: Overview

Table 45 Fresenius Kabi AG: Product Portfolio

Table 46 Fresenius Kabi AG: Key Developments

Table 47 Haemonetics Corporation: Overview

Table 48 Haemonetics Corporation: Product Portfolio

Table 49 Haemonetics Corporation: Key Developments

Table 50 Kawasumi Laboratories: Overview

Table 51 Kawasumi Laboratories: Product Portfolio

Table 52 Kawasumi Laboratories: Key Developments

Table 53 Adcem Healthcare: Overview

Table 54 Adcem Healthcare: Product Portfolio

Table 55 Adcem Healthcare: Key Developments

Table 56 Kochin Inlab Equipments India Pvt Ltd: Overview

Table 57 Kochin Inlab Equipments India Pvt Ltd: Product Portfolio

Table 58 Kochin Inlab Equipments India Pvt Ltd: Key Developments

Table 59 Miltenyi Biotec: Overview

Table 60 Miltenyi Biotec: Product Portfolio

Table 61 Miltenyi Biotec: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 2 Global Therapeutic Plasma Exchange Market Share, By Product Type, 2022 & 2030 (%)

Figure 3 Global Therapeutic Plasma Exchange Market Share, By Indication, 2022 & 2030 (%)

Figure 4 Global Therapeutic Plasma Exchange Market Share, By End-User, 2022 & 2030 (%)

Figure 5 Global Therapeutic Plasma Exchange Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Therapeutic Plasma Exchange Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 7 Apheresis Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 8 Filters Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 9 Others Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 10 Global Therapeutic Plasma Exchange Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 11 Neurological Disorders Indication in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 12 Cardiovascular Disorders Indication in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 13 Hematology Disorders Indication in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 14 Renal Disorders Indication in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 15 Others Indication in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 16 Global Therapeutic Plasma Exchange Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 17 Hospitals End-User in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 18 Ambulatory Surgical Centers End-User in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 19 Others End-User in Global Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 20 Global Therapeutic Plasma Exchange Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 24 South America Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 26 North America Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 27 North America Therapeutic Plasma Exchange Market Share, By Product Type, 2022 & 2030 (%)

Figure 28 North America Therapeutic Plasma Exchange Market Share, By Indication, 2022 & 2030 (%)

Figure 29 North America Therapeutic Plasma Exchange Market Share, By End-User, 2022 & 2030 (%)

Figure 30 North America Therapeutic Plasma Exchange Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 32 South America Therapeutic Plasma Exchange Market Share, By Product Type, 2022 & 2030 (%)

Figure 33 South America Therapeutic Plasma Exchange Market Share, By Indication, 2022 & 2030 (%)

Figure 34 South America Therapeutic Plasma Exchange Market Share, By End-User, 2022 & 2030 (%)

Figure 35 South America Therapeutic Plasma Exchange Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Therapeutic Plasma Exchange Market Share, By Product Type, 2022 & 2030 (%)

Figure 38 Europe Therapeutic Plasma Exchange Market Share, By Indication, 2022 & 2030 (%)

Figure 39 Europe Therapeutic Plasma Exchange Market Share, By End-User, 2022 & 2030 (%)

Figure 40 Europe Therapeutic Plasma Exchange Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Therapeutic Plasma Exchange Market Share, By Product Type, 2022 & 2030 (%)

Figure 43 Asia-Pacific Therapeutic Plasma Exchange Market Share, By Indication, 2022 & 2030 (%)

Figure 44 Asia-Pacific Therapeutic Plasma Exchange Market Share, By End-User, 2022 & 2030 (%)

Figure 45 Asia-Pacific Therapeutic Plasma Exchange Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Therapeutic Plasma Exchange Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Therapeutic Plasma Exchange Market Share, By Product Type, 2022 & 2030 (%)

Figure 48 Middle East & Africa Therapeutic Plasma Exchange Market Share, By Indication, 2022 & 2030 (%)

Figure 49 Middle East & Africa Therapeutic Plasma Exchange Market Share, By End-User, 2022 & 2030 (%)

Figure 50 Asahi Kasei Corporation: Financials

Figure 51 Baxter International Inc: Financials

Figure 52 Terumo Corporation: Financials

Figure 53 B. Braun Melsungen AG: Financials

Figure 54 Fresenius Kabi AG: Financials

Figure 55 Haemonetics Corporation: Financials

Figure 56 Kawasumi Laboratories: Financials

Figure 57 Adcem Healthcare: Financials

Figure 58 Kochin Inlab Equipments India Pvt Ltd: Financials

Figure 59 Miltenyi Biotec: Financials

글로벌 치료용 혈장 교환 시장 – 2023-2030

Global Therapeutic Plasma Exchange Market - 2023-2030